Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02052648|
Recruitment Status : Completed
First Posted : February 3, 2014
Last Update Posted : August 21, 2019
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma Multiforme Glioma Gliosarcoma Malignant Brain Tumor||Drug: Indoximod Drug: Temozolomide Drug: Bevacizumab Radiation: Stereotactic Radiation||Phase 1 Phase 2|
The aim of this study is to identify the safety profile and the recommended dose for phase 2 study of the combination of indoximod (portion 1, phase 1b study). Investigators will then evaluate the tolerability and the preliminary activity in patients with recurrent GBM in three different situations:
- Combination of indoximod and temozolomide (bevacizumab-naive patients)
- Combination of indoximod and temozolomide in patients currently receiving or having received and failed bevacizumab.
- Combination of indoximod and temozolomide with stereotactic radiation. Ancillary studies will be conducted to assess the correlation between intra-tumoral IDO expression or serum biomarkers (immune monitoring) and treatment efficacy.
If the current study shows an acceptable safety profile and suggests preliminary evidence of activity, this will provide the justification for subsequent randomized phase 2 studies in refractory glioblastoma multiforme (GBM).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors|
|Study Start Date :||March 2014|
|Actual Primary Completion Date :||April 18, 2018|
|Actual Study Completion Date :||June 20, 2019|
Experimental: Phase 1b Cohort 1
Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle.
Temozolomide will also be given by mouth at 150 mg/m^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity.
Experimental: Cohort 2a
Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
Experimental: Cohort 2b
Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab.
Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg.
Other Name: Avastin
Experimental: Cohort 2c
Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
Radiation: Stereotactic Radiation
Other Name: SRS or SRT
- Phase 1: Determine Phase 2 Dosing [ Time Frame: 3 months ]
Phase 1b component:
Primary objective is to determine the recommended Phase 2 dose of indoximod and temozolomide in combination for treatment of progressive high-grade glioma (including glioblastoma multiforme) or gliosarcoma.
- Phase 2: Efficacy [ Time Frame: 18 months ]Six-month progression-free survival.
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 1 year ]
Phase 1b component:
To determine the adverse event profile (event type, incidence severity, duration causality and treatment intervention) and identify regimen-limiting toxicities (RLT) of indoximod plus temozolomide in combination therapy.
Specifically, investigators define regimen-limiting toxicity (RLT) as a toxicity that delays the planned administration of the next cycle of the backbone chemotherapy. The goal of the trial will be to find the maximum dose of indoximod that does not induce RLT in more than 1/6 of patients treated with temozolomide.
- Overall Dose of Temozolomide Delivered Versus Historical Control [ Time Frame: 1 year ]To test the hypothesis that the addition of indoximod will not reduce the overall dose of temozolomide delivered or delay the timing of administration, compared to historical controls using T-test.
- Serum concentrations (Cmax/Steady State) of indoximod HLC [ Time Frame: 1 year ]
Phase 1b component:
To determine the pharmacokinetic profile of indoximod in the setting of this treatment regimen. A thorough pharmacokinetic (PK) profile will be performed for each patient entered into the study through analysis of blood samples collected at protocol-defined time points.
- Overall response rate [ Time Frame: 18 months ]Assessed for Arms 2a, 2b and 2c
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 18 Months ]Assessed for Arms 2a, 2b and 2c
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02052648
|United States, California|
|Eden Medical Center|
|Castro Valley, California, United States, 94546|
|Cedars-Sinai Medical Center|
|Los Angeles, California, United States, 90048|
|UC Irvine Chao Family Comprehensive Cancer Center|
|Orange, California, United States, 92868|
|United States, Florida|
|Moffitt Cancer Center|
|Tampa, Florida, United States, 33612|
|United States, Georgia|
|University Cancer and Blood Center|
|Athens, Georgia, United States, 30607|
|Children's Healthcare of Atlanta|
|Atlanta, Georgia, United States, 30342|
|Augusta, Georgia, United States, 30912|
|United States, Illinois|
|University of Chicago|
|Chicago, Illinois, United States, 60637|
|United States, Iowa|
|University of Iowa Hospitals and Clinics|
|Iowa City, Iowa, United States, 52242|
|United States, Kentucky|
|University of Kentucy|
|Lexington, Kentucky, United States, 40536|
|United States, Minnesota|
|John Nasseff Neuroscience Institute|
|Minneapolis, Minnesota, United States, 55407|
|United States, New Mexico|
|University of New Mexico Comprehensive Cancer Center|
|Albuquerque, New Mexico, United States, 87131|
|United States, North Carolina|
|Wake Forest Baptist Health Comprehensive Cancer Center|
|Winston-Salem, North Carolina, United States, 27157|
|United States, Pennsylvania|
|Penn State Hershey Medical Center|
|Hershey, Pennsylvania, United States, 17033|
|United States, Texas|
|Austin, Texas, United States, 78705|
|United States, Utah|
|Huntsman Cancer Center|
|Salt Lake City, Utah, United States, 84112|
|United States, Virginia|
|Virginia Cancer Specialists|
|Fairfax, Virginia, United States, 22031|